Načítá se...
Reducing Polycystic Liver Volume in ADPKD: Effects of Somatostatin Analogue Octreotide
Background and objectives: No medical treatment is available for polycystic liver disease, a frequent manifestation of autosomal-dominant polycystic kidney disease (ADPKD). In a prospective, randomized, double-blind, crossover study, 6 months of octreotide (40 mg every 28 days) therapy limited kidne...
Uloženo v:
| Hlavní autoři: | , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Society of Nephrology
2010
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2863977/ https://ncbi.nlm.nih.gov/pubmed/20185596 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.05380709 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|